1
|
Basic characteristics and safety of donation in related and unrelated haematopoietic progenitor cell donors - first 10 years of prospective donor follow-up of Swiss donors. Bone Marrow Transplant 2022; 57:918-924. [PMID: 35379914 DOI: 10.1038/s41409-022-01656-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Revised: 03/17/2022] [Accepted: 03/22/2022] [Indexed: 11/08/2022]
Abstract
Since July 2007 prospective life-long follow-up (FU) for unrelated (URD) and related donors (RD) is mandatory in Switzerland and data on every allogeneic haematopoietic progenitor cell (HPC) donation are collected prospectively. We report the real-world experience of HPC donation during a 10-year study period (01.07.2007-30.06.2017) with basic characteristics and FU data. 1105 donors underwent 1155 HPC donation procedures. Eighty percent of first donations performed by 802 (73%) RDs and 303 (27%) URDs were peripheral blood stem cells (PBSC), 20% bone marrow (BM). Male donors were over-represented as URD (60% male vs 40% female). Main differences between RDs and URDs concerned age and pre-existing health disorders. RDs were significantly older at first donation (median age 48 years) compared to URD (34 years, p < 0.0001) and had more pre-existing health problems: 25% vs 9% in URD (p < 0.0001). No fatal complications occurred, collection related severe adverse events (SAE) after first donation were not significantly different between groups (RD 1.2%, URD 0.99%), incidence rates for neoplastic and autoimmune diseases did not exceed the rates of the general population. RDs are a more heterogeneous and potentially more vulnerable group, but if donor evaluation is performed appropriately, HPC donation is still safe.
Collapse
|
2
|
Fernandez-Sojo J, Azqueta C, Valdivia E, Martorell L, Medina-Boronat L, Martínez-Llonch N, Torrents S, Codinach M, Canals C, Elorza I, Parody R, Martino R, Trabazo M, Díaz de Heredia C, Ferra C, Valcárcel D, Linares M, Ancochea Á, García-Rey E, García-Muñoz N, Medina L, Castillo N, Carreras E, Villa J, Querol S. Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic? Bone Marrow Transplant 2021; 56:2489-2496. [PMID: 34127808 PMCID: PMC8201455 DOI: 10.1038/s41409-021-01367-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2020] [Revised: 05/16/2021] [Accepted: 05/26/2021] [Indexed: 12/02/2022]
Abstract
Cryopreservation was recommended to ensure continuity of unrelated donor (UD) hematopoietic stem cell transplantation (HSCT) during COVID-19 pandemic. However, its impact on clinical outcomes and feasibility was not well known. We compared 32 patients who underwent UD HSCT using cryopreserved peripheral blood stem cells (PBSC) during the COVID-19 pandemic with 32 patients who underwent UD HSCT using fresh PBSC in the previous period. Median neutrophil engraftment was 17.5 and 17.0 days with cryopreserved and fresh grafts, respectively. Non-significant delays were found in platelet recovery days (25.5 versus 19.0; P = 0.192) and full donor chimerism days (35.0 and 31.5; P = 0.872) using cryopreserved PBSC. The rate of acute graft-versus-host disease at 100 days was 41% (95% CI [21-55%]) in cryopreserved group versus 31% (95% CI [13-46%]) in fresh group (P = 0.380). One-hundred days progression-relapse free survival and overall survival did not differ significantly. During COVID-19 pandemic, six frozen UD donations were not transfused and logistical and clinical issues regarding cryopreservation procedure, packaging, and transporting appeared. In summary, UD HSCT with cryopreserved PBSC was safe during this challenging time. More efforts are needed to ensure that all frozen grafts are transplanted and cryopreservation requirements are harmonized.
Collapse
Affiliation(s)
- Jesus Fernandez-Sojo
- Línia de recerca d'Oncologia i Hematologia, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain.
- Banc de Sang i Teixits, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | - Izaskun Elorza
- Pediatric Hematology Department, Hospital Sant Joan de Déu, Barcelona, Spain
| | - Rocio Parody
- Adult Hematology Department, Institut Catala d'Oncologia-Hospitalet, Barcelona, Spain
| | - Rodrigo Martino
- Adult Hematology Department, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Maria Trabazo
- Pediatric Hematology Department, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain
| | | | - Christelle Ferra
- Adult Hematology Department, Institut Català d'Oncologia-Badalona, Barcelona, Spain
| | - David Valcárcel
- Adult Hematology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - Mónica Linares
- Banc de Sang i Teixits, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - Águeda Ancochea
- Banc de Sang i Teixits, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | - Enric García-Rey
- Banc de Sang i Teixits, Hospital Sant Joan de Déu, Barcelona, Spain
| | - Nadia García-Muñoz
- Banc de Sang i Teixits, Hospital Universitari de Bellvitge, H. Llobregat, Barcelona, Spain
| | - Laura Medina
- Banc de Sang i Teixits, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Nerea Castillo
- Banc de Sang i Teixits, Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain
| | - Enric Carreras
- Spanish Bone Marrow Donor Registry, Josep Carreras Foundation and Leukemia Research Institute, Barcelona, Catalunya, Spain
| | - Juliana Villa
- Spanish Bone Marrow Donor Registry, Josep Carreras Foundation and Leukemia Research Institute, Barcelona, Catalunya, Spain
| | | |
Collapse
|
5
|
O'Leary MF, Dunbar NM, Kim HC, Draper NL, Linenberger M, Schwartz J, Miller Y, Murtaugh A, West FB, Fernando LP, Park YA. Venous access for hematopoietic progenitor cell collection: An international survey by the ASFA HPC donor subcommittee. J Clin Apher 2016; 31:529-534. [DOI: 10.1002/jca.21445] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2015] [Revised: 12/08/2015] [Accepted: 12/17/2015] [Indexed: 11/08/2022]
Affiliation(s)
- Mandy Flannery O'Leary
- University Medical Center New Orleans; New Orleans Louisiana
- The Blood Center; New Orleans Louisiana
- Department of Pathology; Louisiana State University Health Sciences Center; New Orleans Louisiana
| | - Nancy M. Dunbar
- Department of Pathology; Dartmouth-Hitchcock Medical Center; Lebanon New Hampshire
| | - Haewon C. Kim
- Children's Hospital of Philadelphia; Philadelphia Pennsylvania
- Perelman School of Medicine; University of Pennsylvania; Philadelphia Pennsylvania
| | - Nicole L. Draper
- University of Colorado Hospital; Aurora Colorado
- Department of Pathology; University of Colorado School of Medicine; Aurora Colorado
| | - Michael Linenberger
- Department of Medicine; Division of Hematology; University of Washington; Seattle Washington
- Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle Washington
- Seattle Cancer Care Alliance; Seattle Washington
| | - Joseph Schwartz
- Department of Pathology and Cell Biology; Columbia University Medical Center; New York New York
| | - Yvette Miller
- American Red Cross; Donor and Client Support Center; Charlotte North Carolina
| | | | | | | | - Yara A. Park
- Department of Pathology and Laboratory Medicine; University of North Carolina; Chapel Hill North Carolina
- The Blood Center; New Orleans Louisiana
| |
Collapse
|